Daiichi Sankyo Europe and Esperion Announce Validation of the Marketing Authorisation Application (MAA) for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet

[In The News]

MUNICH and ANN ARBOR, Michigan, Feb. 28, 2019 /PRNewswire/ -- Application is based on results of a robust development programme, which demonstrated that bempedoic acid was well tolerated and efficacious for chronic use Bempedoic acid is a first-in-class, oral, once-daily ATP Citrate Lyase ...

View the full article